Literature DB >> 33841683

Comparison of self-expandable stents and balloon-mounted stents in the treatment of symptomatic intracranial vertebral artery atherosclerotic stenosis.

Chunou Tian1, Bin Liu2, Jianmin Liu3, Bo Hong3, Puyuan Zhao4, Liangliang Yang4, Qiuping Li4, Zhigang Yang4.   

Abstract

OBJECTIVE: To compare the safety and efficacy of self-expandable stents (SES) and balloon-mounted stents (BMS) in the treatment of severe symptomatic intracranial vertebral artery atherosclerotic stenosis (SIVAAS).
METHODS: The clinical and imaging data of 76 consecutive cases who were stented for SIVAAS in our centers in ten years were reviewed retrospectively. The cases were divided into SES group and BMS group as per the type of stents. Conventional risk factors of atherosclerosis, the relationship between stenosis and the origin of posterior inferior cerebellar artery (PICA), whether the stenosis was located at the dural-entry zone of the vertebral artery (VA), the interventional access, periprocedural complications, and clinical and imaging follow-up results were analyzed statistically.
RESULTS: 77 stenotic lesions in 76 cases were included. Totally 51 SES and 26 BMS were implanted successfully. There was no significant difference in periprocedural complications (1 vs. 2, P = 0.544), incidence of restenosis (13.2% vs. 14.3%, P = 0.628) and long-term death or stroke (4 vs. 7, P = 0.33) between the two groups. The degree of residual stenosis in SES group was higher than in BMS group (10 (0%-40%) vs. 0 (0%-15%); P = 0). More BMS were selected in lesions located at the dural-entry zone of VA (45.1% vs. 73.1%, P = 0.02). There were more BMS implanted when lesions located proximal to origin of PICA (SES vs. BMS = 23.5% vs. 57.7%, P = 0.003) or when lesions with straighter access (SES vs. BMS = 29.4% vs. 69.2%, P = 0.001). More SES implanted when lesions located distal to PICA (SES vs. BMS = 43.1% vs. 15.4%, P = 0.015) or when lesions with moderate tortuous access (SES vs. BMS = 60.8% vs. 23.1%, P = 0.002). For stenotic lesions with moderate tortuous interventional access, SES group cases had longer survival time without stroke or death (P = 0.008).
CONCLUSION: Both SES and BMS showed high safety and efficacy for the treatment of SIVAAS. SES was more recommended for the stenotic lesions with tortuous interventional access. BMS was more recommended for the lesions located at the dural-entry zone of VA or proximal to PICA origin. AJTR
Copyright © 2021.

Entities:  

Keywords:  Self-expandable stent; balloon-mounted stent; intracranial atherosclerotic stenosis; intracranial vertebral artery; vertebral artery stenosis

Year:  2021        PMID: 33841683      PMCID: PMC8014385     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  25 in total

1.  Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.

Authors:  Ka Sing Lawrence Wong; Christopher Chen; Jianhui Fu; Hui Meng Chang; Nijasri C Suwanwela; Yining N Huang; Zhao Han; Kay Sin Tan; Disya Ratanakorn; Pavithra Chollate; Yudong Zhao; Angeline Koh; Qing Hao; Hugh S Markus
Journal:  Lancet Neurol       Date:  2010-03-22       Impact factor: 44.182

Review 2.  A systematic review on outcome after stenting for intracranial atherosclerosis.

Authors:  Klaus Gröschel; Sonja Schnaudigel; Sara M Pilgram; Katrin Wasser; Andreas Kastrup
Journal:  Stroke       Date:  2009-01-29       Impact factor: 7.914

3.  Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial.

Authors:  Annette Compter; H Bart van der Worp; Wouter J Schonewille; Jan Albert Vos; Jelis Boiten; Paul J Nederkoorn; Maarten Uyttenboogaart; Rob T Lo; Ale Algra; L Jaap Kappelle
Journal:  Lancet Neurol       Date:  2015-04-20       Impact factor: 44.182

4.  A link between stent radial forces and vascular wall remodeling: the discovery of an optimal stent radial force for minimal vessel restenosis.

Authors:  Joseph W Freeman; Patrick B Snowhill; John L Nosher
Journal:  Connect Tissue Res       Date:  2010-08       Impact factor: 3.417

5.  Subtyping of ischemic stroke based on vascular imaging: analysis of 1,167 acute, consecutive patients.

Authors:  Jin T Kim; Sung H Yoo; Jee-Hyun Kwon; Sun U Kwon; Jong S Kim
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

6.  Balloon-Mounted versus Self-Expanding Stent Outcomes in Symptomatic Middle Cerebral Artery Stenosis Combined with Poor Collaterals in China: A Multicenter Registry Study.

Authors:  Guangwen Li; Naidong Wang; Xin Li; Ning Ma; Tonghui Liu; Yujie Sun; Peng Liu; Zhongrong Miao; Yong Zhang
Journal:  World Neurosurg       Date:  2019-01-16       Impact factor: 2.104

7.  Multicenter Prospective Trial of Stent Placement in Patients with Symptomatic High-Grade Intracranial Stenosis.

Authors:  P Gao; D Wang; Z Zhao; Y Cai; T Li; H Shi; W Wu; W He; L Yin; S Huang; F Zhu; L Jiao; X Ji; A I Qureshi; F Ling
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-11       Impact factor: 3.825

8.  Relationship between neointimal thickness and shear stress after Wallstent implantation in human coronary arteries.

Authors:  J J Wentzel; R Krams; J C Schuurbiers; J A Oomen; J Kloet; W J van Der Giessen; P W Serruys; C J Slager
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

9.  Stenting of symptomatic M1 stenosis of middle cerebral artery: an initial experience of 40 patients.

Authors:  Wei-Jian Jiang; Yong-Jun Wang; Bin Du; Su-Xiang Wang; Gui-Hong Wang; Min Jin; Jian-Ping Dai
Journal:  Stroke       Date:  2004-05-06       Impact factor: 7.914

10.  The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis.

Authors:  O O Zaidat; R Klucznik; M J Alexander; J Chaloupka; H Lutsep; S Barnwell; M Mawad; B Lane; M J Lynn; M Chimowitz
Journal:  Neurology       Date:  2008-01-30       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.